<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02202603</url>
  </required_header>
  <id_info>
    <org_study_id>0020-11-HMO-EnteraBio</org_study_id>
    <nct_id>NCT02202603</nct_id>
  </id_info>
  <brief_title>A Three Stage, Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of Oral PTH (1-34) in Healthy Subjects</brief_title>
  <official_title>A Three Stage, Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of Oral PTH (1-34) in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Entera Bio Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Entera Bio Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Double blinded (oral), Open Label, Study to Assess the Safety, Pharmacokinetics and
      Pharmacodynamics of Oral PTH (1-34) in healthy Subjects to establish the safety,
      tolerability, bioavailability, pharmacokinetic, and pharmacodynamic profile and the of
      Entera's oral PTH(1 - 34) in adult healthy human volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will have three stages. Stage 1: Safety and initial bioavailability of Entera's
      oral EP101 in adult male healthy volunteers. (SA-BA) Stage 2: Assessment of bioavailability
      and safety of Entera's oral EP101 in adult male healthy volunteers. (SA-BA-PK-PD) Stage 3:
      Safety, PK, and PD of final dose of Entera's oral PTH(1 - 34) in adult healthy male and
      female volunteers. (SA-BA-PK-PD)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>up to 17 weeks</time_frame>
    <description>throughout the study beginning from the time the subject signs the consent form until the end of study, subjects will complete the following evaluations:
Vital signs (blood pressure, heart rate, oral temperature)
Clinical laboratory evaluations, hematology, chemistry
Physical Exam
ECG</description>
  </primary_outcome>
  <number_of_arms>13</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Drug Safety</condition>
  <arm_group>
    <arm_group_label>Teriparatide group 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subcutaneous injection of Teriparatide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>excipients</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral pill without API</description>
  </arm_group>
  <arm_group>
    <arm_group_label>API</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral administration of pill with API</description>
  </arm_group>
  <arm_group>
    <arm_group_label>API optimization 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral administration of pill with API, for PK optimization #1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>API optimization 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral administration of pill with API, for PK optimization #2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>API optimization 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral administration of pill with API, for PK optimization #3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>API optimization 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral administration of pill with API, for PK optimization #4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>API optimization 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral administration of pill with API, for PK optimization #5</description>
  </arm_group>
  <arm_group>
    <arm_group_label>API optimization 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral administration of pill with API, for PK optimization #6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>API optimization 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral administration of pill with API, for PK optimization #7</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Teriparatide group 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subcutaneous injection of Teriparatide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Excipients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral pill without API</description>
  </arm_group>
  <arm_group>
    <arm_group_label>API Optimized</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>expanded group size with API in optimized dosage and administration form.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Teriparatide</intervention_name>
    <description>single oral tablet</description>
    <arm_group_label>API</arm_group_label>
    <arm_group_label>API optimization 1</arm_group_label>
    <arm_group_label>API optimization 2</arm_group_label>
    <arm_group_label>API optimization 3</arm_group_label>
    <arm_group_label>API optimization 4</arm_group_label>
    <arm_group_label>API optimization 5</arm_group_label>
    <arm_group_label>API optimization 6</arm_group_label>
    <arm_group_label>API optimization 7</arm_group_label>
    <arm_group_label>API Optimized</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Teriparatide</intervention_name>
    <description>subcutaneous standard injection</description>
    <arm_group_label>Teriparatide group 1</arm_group_label>
    <arm_group_label>Teriparatide group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Oral placebo</description>
    <arm_group_label>excipients</arm_group_label>
    <arm_group_label>Excipients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ● Signed Informed consent to the study.

               -  Male and female volunteers ,aged 18 - 50 years, BMI 18-30 kg/m2, inclusive,

               -  Subjects able to adhere to the visit schedule and protocol requirements

               -  Hematology ,Chemistry and Urinalysis values with no clinical significance or do
                  not reflect a medical condition which according to the physicians' judgment might
                  confound the results of the study or pose additional risk to the subject by
                  participation in the study.

               -  Hemoglobin level &gt;. 12.5 g/dl

               -  Blood pressure levels with no clinical significance.

               -  Negative serology to HIV, Hepatitis B, Hepatitis C.

               -  No known drug and alcohol abuse

               -  Negative urinary drugs of abuse at screening

               -  No allergy to soy bean products.

               -  No prescription medications taken within one month to enrollment

               -  Over-the-counter drugs (including vitamins) taken within 14 days prior to visit 2
                  are subject to the investigators' discretion for inclusion.

               -  No subjects with previous urolithiasis.

               -  Non-smoking,

               -  In good health as determined by past medical history, physical examination, vital
                  signs, electrocardiogram and laboratory tests at screening

        Exclusion Criteria:

          -  ● Concurrent therapy that, in the Investigator's opinion, would interfere with the
             evaluation of the safety or efficacy of the study medication.

               -  Treatment with any investigational product within the last 30 days, enrollment or
                  intention to enroll in any active study involving the use of investigational
                  devices or drugs.

               -  Presence of any other condition or circumstance that, in the judgment of the
                  Investigator, might increase the risk to the patient or decrease the chance of
                  obtaining satisfactory data to achieve the objectives of the study.

               -  Active infections

               -  History of drug or alcohol abuse

               -  Known allergies or sensitivities to components of study treatment or study
                  procedures, including Soy.

               -  Clinically diagnosed psychiatric disorders that may interfere with patient study
                  participation

               -  Medical history known or suspected to increase risks of AEs related to study
                  drug, up to the investigator's discretion

               -  Chronic illnesses, up to the investigator's discretion

               -  Female subjects must have a negative serum pregnancy test at screening and be
                  willing and able to use a medically acceptable method of birth control
                  (non-hormonal intrauterine device with condom, or diaphragm with condom, or
                  condom with spermicide) from the screening visit through the study termination
                  visit or declare that they are abstaining from sexual intercourse from the
                  screening visit through the study termination visit or are surgically sterile
                  (have undergone bilateral tubal ligation, bilateral oophorectomy, or
                  hysterectomy) or post menopausal. Postmenopausal women are defined as women with
                  menstruation cessation for 12 consecutive months prior to signing of the informed
                  consent form.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yosef Caraco, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hadassah Ein Kerem Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>HMO Clinical Research Center Hadassah Ein Kerem Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120,</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 20, 2011</study_first_submitted>
  <study_first_submitted_qc>July 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2014</study_first_posted>
  <last_update_submitted>October 6, 2015</last_update_submitted>
  <last_update_submitted_qc>October 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 7, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Teriparatide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

